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NEW VIRAL AND NON-VIRAL PLATFORMS FOR T-CELL ENGINEERING 
 




FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise 
than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for 
this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-
viral delivery approaches used in T cell engineering for cell and gene therapy applications including: 
 
 New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral 
Production System 
o Platform development process using Design of Experiment (DOE) methodologies 
o High-throughput to large scale bioreactor protocols 
o Cost benefits of this system over current methods 
 
 Novel gene editing tools for primary T cells 
o New potent gene editing tools to increase knock-in and knock-out efficiency 
o Addressing non-viral delivery barriers through protocol optimization 
 
Learning Objectives: 
 Current industry trends and challenges of cell and gene therapy manufacturing 
 Benefits of innovative new upstream technologies for virus generation in suspension 
 
 
 
